Novo Nordisk, JDRF collaborating on R&D for type 1 diabetes

To address the underlying autoimmune process that is central to type 1 diabetes, JDRF and Novo Nordisk are partnering to discover and develop novel immunotherapies to prevent, treat, and help cure the disease, the companies announced. The collaboration between JDRF and Novo Nordisk will focus on research originating from academia and biotechnology companies, as well as from internal research projects at Novo Nordisk.